Compare CALX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALX | MIRM |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 2010 | 2019 |
| Metric | CALX | MIRM |
|---|---|---|
| Price | $53.82 | $69.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $77.75 | ★ $82.82 |
| AVG Volume (30 Days) | ★ 692.8K | 536.5K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $933,685,000.00 | $471,794,000.00 |
| Revenue This Year | $19.95 | $53.14 |
| Revenue Next Year | $12.89 | $19.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.89 | ★ 53.66 |
| 52 Week Low | $28.61 | $36.88 |
| 52 Week High | $71.22 | $78.55 |
| Indicator | CALX | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 35.55 | 44.02 |
| Support Level | $53.31 | $68.60 |
| Resistance Level | $54.81 | $71.98 |
| Average True Range (ATR) | 1.74 | 2.55 |
| MACD | -0.19 | -0.09 |
| Stochastic Oscillator | 31.08 | 7.55 |
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.